| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Psoralen (psoralene, Ficusin, Furocoumarin) is a naturally occurring furocoumarin isolated from Fructus Psoraleae, it intercalates with DNA, inhibiting DNA synthesis and cell division. Psoralen prevents rather than promotes apoptosis in MCF-7/ADR cell proliferation, as evidenced by G0/G1 phase arrest. Psoralen inhibits ATPase activity instead of decreasing P-gp expression to reverse MDR (multidrug resistance). Psoralen represses EMT, potentially by preventing NF-κB activation, which limits the migration potential of MCF-7/ADR cells. When longwave UV light activates pristralens, a class of photoactive compounds, DNA is easily alkylated.
| ln Vitro |
Psoralen prevents rather than promotes apoptosis in MCF-7/ADR cell proliferation, as evidenced by G0/G1 phase arrest. Psoralen inhibits ATPase activity instead of decreasing P-gp expression to reverse MDR (multidrug resistance). Psoralen represses EMT, potentially by preventing NF-κB activation, which limits the migration potential of MCF-7/ADR cells. When longwave UV light activates pristralens, a class of photoactive compounds, DNA is easily alkylated. When MCF-7/ADR cells are exposed to low concentrations of psoralen (<10.75 µM) and high concentrations (>21.5 µM), their proliferation is markedly enhanced. Breast cancer metastases can be prevented by prisoralen. Numerous cell processes, such as migration, proliferation, inflammation, and death, are mediated by psoralen[1].
|
|---|---|
| ln Vivo |
Psoralen has been identified as a tumor suppressor in a number of different tumors[1]. In both male and female mice, psoralen reduces osteoporosis brought on by a lack of sex hormone. By promoting osteoblastic differentiation from bone mesenchymal stem cells, it has an antiosteoporosis effect in rats with osteoporotic ovariectomy[2].
|
| Cell Assay |
The MTT assay is used to measure the effects of psoralen on cell proliferation. MCF-10A and MCF-7/ADR cells are cultivated for 48 hours at a cell density of 2×104 per well in 96-well plates. After that, the medium is taken out and replaced with new medium that has varying amounts of psoralen (0, 21.5, 43.0, 64.5, 86.0, and 107.5 μM) for 48 hours. The negative control group's cells are cultured in RPMI-1640 culture medium with 0.1% dimethyl sulfoxide (DMSO) added as a supplement. After incubating the cells for four hours with 10 µL MTT (5 mg/mL), the medium is discarded and 200 µL DMSO is added. After the crystals have completely dissolved, the spectrophotometric absorbance is measured at 490 nm using an enzyme-labeling apparatus.
|
| Animal Protocol |
ICR mice
10 mg/kg and 20 mg/kg intragastrically |
| References |
| Molecular Formula |
C11H6O3
|
|
|---|---|---|
| Molecular Weight |
186.16
|
|
| Exact Mass |
186.03
|
|
| CAS # |
66-97-7
|
|
| Related CAS # |
|
|
| Appearance |
Powder
|
|
| SMILES |
C1=CC(=O)OC2=CC3=C(C=CO3)C=C21
|
|
| InChi Key |
ZCCUUQDIBDJBTK-UHFFFAOYSA-N
|
|
| InChi Code |
InChI=1S/C11H6O3/c12-11-2-1-7-5-8-3-4-13-9(8)6-10(7)14-11/h1-6H
|
|
| Chemical Name |
furo[3,2-g]chromen-7-one
|
|
| Synonyms |
|
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
|
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
|
|||
|---|---|---|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (13.43 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 2.5 mg/mL (13.43 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (13.43 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.3717 mL | 26.8586 mL | 53.7172 mL | |
| 5 mM | 1.0743 mL | 5.3717 mL | 10.7434 mL | |
| 10 mM | 0.5372 mL | 2.6859 mL | 5.3717 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT04389281 | Recruiting | Combination Product: X-PACT | Advanced Solid Tumor Cancer | Immunolight, LLC | December 8, 2021 | Phase 1 |
| NCT00005092 | Completed | Drug: Psoralen Drug: Thiotepa |
Leukemia Lymphoma |
M.D. Anderson Cancer Center | May 28, 1999 | Phase 1 |
| NCT01526213 | Completed | Drug: Fexofenadine | Food-drug Interaction | University of North Carolina, Chapel Hill |
September 2009 | Not Applicable |
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
